Chimeric antigen receptor and application thereof

A technology of chimeric antigen receptors and antigens, applied in medicine, in the field of chimeric antigen receptors, can solve problems such as low expression levels

Active Publication Date: 2020-08-07
GUANGZHOU BIO GENE TECH CO LTD
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Related targets of B cells also include CD20 and CD22, etc., but their expression levels in B cell leukemia and lymphoma are much lower than CD19

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Chimeric antigen receptor and application thereof
  • Chimeric antigen receptor and application thereof
  • Chimeric antigen receptor and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1B

[0083] Example 1 Design and function of BAFF antigen-binding domain

[0084] In order to use BAFF as the antigen-binding domain of the CAR molecule, the soluble BAFF was modified in this example, and the amino acid VHVFGDEL, which is necessary for the activation of positions 217-224 of the soluble BAFF (soluble form: 134-285), was replaced with GG, The modified BAFF shown in SEQ ID NO:1 was obtained.

[0085] (1) Binding ability of modified BAFF to BAFF-R

[0086] The results are shown in Table 1. The modified BAFF (mBAFF) lost the BAFF activation ability, but retained the BAFF-R binding ability.

[0087] Table 1 Analysis of the binding of recombinant BAFF and modified protein to K562-BAFFR cells

[0088] target protein Mean Fluorescence Intensity (MFI) binding positive rate wild soluble BAFF 856 59.35% Transformation of soluble BAFF 969 62.56% Wild soluble BAFF trimer 2968 97.45% Modified soluble BAFF trimer 2565 95.67% PBS 25...

Embodiment 2

[0092] Embodiment 2 Design of CAR molecules

[0093] In this example, the engineered BAFF shown in SEQ ID NO: 1 is used as the antigen-binding domain to construct a monomeric BAFF-based chimeric antigen receptor (BAFF CAR) as shown in Figure 3 (A) and a trimeric BAFF-based The chimeric antigen receptor (TriBAFF CAR) of the body BAFF (TriBAFF CAR), the three BAFFs in the TriBAFF CAR molecule are connected by a GGGGS linker, which recognizes and binds to BAFF-R; The CD19 CAR of the CD19 antibody (FMC63) scFv specifically recognizes the CD19 antigen.

[0094] In addition to the antigen-binding domain, the above-mentioned CAR molecule also includes a CD8α signal peptide sequence (Leader), a CD8α hinge region (Hinge) and a transmembrane region (Transmembrane) sequence, a 4-1BB co-stimulatory domain sequence and a CD3ζ signaling domain sequence.

Embodiment 3

[0095] The construction of embodiment 3 lentiviral vectors

[0096] (1) Whole gene synthesis of nucleic acid molecules of the following CAR molecules:

[0097] BAFF CAR: composed of CD8a signal peptide sequence, modified BAFF sequence, CD8a hinge region and transmembrane region sequence, 4-1BB and CD3ζ in tandem (the amino acid sequence is shown in SEQ ID NO: 8);

[0098] TriBAFF CAR: consists of CD8a signal peptide sequence, three repeats of modified BAFF sequences (connected by GGGGS linker between the three BAFFs), CD8a hinge region and transmembrane region sequence, 4-1BB and CD3ζ in series (amino acid sequence such as Shown in SEQID NO:9);

[0099] CD19 CAR: composed of CD8a signal peptide sequence, CD19 scFv, CD8a hinge region and transmembrane region sequence, 4-1BB and CD3ζ in tandem (the amino acid sequence is shown in SEQ ID NO: 10);

[0100] SEQ ID NO: 10:

[0101] Amino acid sequence of CD19 CAR:

[0102] MALPVTALLLPLALLLHAARPDIQMTQTTSSLSASLGDRVTISCRASQDISKYLNW...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a chimeric antigen receptor and application thereof. According to the chimeric antigen receptor, modified BAFF is adopted as an antigen binding structural domain, the modified BAFF retains the BAFF-R bonding capability, however, malignant B cell proliferation caused by BAFF activation cannot be caused, the constructed CAR molecule can recognize and combine BAFF-R, so that the prepared CAR-T cell has a specific targeted killing effect on BAFF-R positive and CD19 negative B tumor cells, and is expected to become a new means for treating tumor recurrence caused by CD19 antigen deletion.

Description

technical field [0001] The invention belongs to the field of biological technology and the technical field of cellular immunotherapy of diseases, and relates to a chimeric antigen receptor and its application, in particular to a chimeric antigen receptor targeting BAFF-R positive tumor cells and its preparation Application of drugs for treating tumor recurrence caused by CD19 antigen deficiency. Background technique [0002] Chimeric antigen receptor (CAR) T cells have been widely used in the treatment of B-cell malignancies, and CAR-T cells targeting CD19 are the pioneers of CAR-T therapy for B-cell malignancies, providing an effective treatment for B-cell malignancies. Program. However, tumor recurrence caused by the loss of CD19 antigen greatly weakens the therapeutic effect. CD19-negative relapse has become an important problem and occurs in approximately 30% of patients. Related targets of B cells also include CD20 and CD22, etc., but their expression levels in B cel...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/705C07K19/00C12N15/62C12N15/867C12N7/01C12N5/10A61K39/00A61P35/00
CPCA61P35/00A61K39/001112C07K14/7051C07K14/70578C07K2319/02C07K2319/03C07K2319/33C12N5/0636C12N7/00C12N15/86C12N2510/00C12N2740/15021C12N2740/15043
Inventor 李光超罗敏周兆丁雯
Owner GUANGZHOU BIO GENE TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products